Skip to main content
padlock icon - secure page this page is secure

Neuroprotective Properties of Nicotine

Buy Article:

$68.00 + tax (Refund Policy)

Utilizing the intrinsic optical signal (IOS) of retinal Spreading Depression (rSD) waves and the concomitant transparency changes of the tissue, we show that nicotine, in an in vivo near tissue preparation, has neuroprotective effects against the excitotoxic cell death, mediated through the activation of glutamate-receptors. For this study the retinal tissue was treated with NMDA, an agonist for the NMDA-glutamate-receptor, being excitotoxic at higher concentrations, to induce tissue damage. The protective effects of nicotine against glutamate induced neurotoxicity are demonstrated, comparing the IOS with NMDA and NMDA + nicotine. We additionally present data about the decrease of the propagation velocity of rSD waves after nicotine application and show analogical effects obtained with epibatidine, a specific nicotinic acetylcholine receptor (nAChR) agonist.

No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: (nAChR) agonist; Epibatidine; NMDA; Nicotine; analogical effects; excitotoxic cell death; neuroprotection; neuroprotective effects; nicotine; spreading depression

Document Type: Research Article

Publication date: January 1, 2012

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more